Anaptysbio Inc Up 8.49% To $17.58 After Earnings Beat

Anaptysbio Inc (ANAB) said after close Thursday that it lost $1.41 per share in quarter three 2023.

On the revenue line, the company reported $3.3 million, beating estimates by $808 thousand.

In the same quarter a year ago, the company lost $1.18 per share on revenue of $1.3 million.

The stock is up 8.49% to $17.58 after the report.

Anaptysbio Inc's revenue expanded at a faster pace than earnings, signaling a decline in profit margins.

Wall Street Analysts had an average rating of Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 29. Meanwhile, the average Wall Street analyst rated the stock a Buy.

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.